کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2190817 | 1097821 | 2011 | 5 صفحه PDF | دانلود رایگان |

Heart failure afflicts ~ 5 million people and causes ~ 300,000 deaths a year in the United States alone. Heart failure is defined as a deficiency in the ability of the heart to pump sufficient blood in response to systemic demands, which results in fatigue, dyspnea, and/or edema. Identifying new therapeutic targets is a major focus of current research in the field. We and others have identified critical roles for protein kinase C (PKC) family members in programming aspects of heart failure pathogenesis. More specifically, mechanistic data have emerged over the past 6–7 years that directly implicate PKCα, a conventional PKC family member, as a nodal regulator of heart failure propensity. Indeed, deletion of the PKCα gene in mice, or its inhibition in rodents with drugs or a dominant negative mutant and/or inhibitory peptide, has shown dramatic protective effects that antagonize the development of heart failure. This review will weigh all the evidence implicating PKCα as a novel therapeutic target to consider for the treatment of heart failure. This article is part of a special issue entitled “Key Signaling Molecules in Hypertrophy and Heart Failure.”
Research Highlights
► Multiple papers have shown that PKCa regulates cardiac contractility.
► Deletion or genetic inhibition of PKCa increases cardiac function and protects from failure.
► Pharmacologic inhibition of PKCa protects from heart failure after injury.
► PKCa inhibitory drugs are promising therapeutics for human heart failure.
Journal: Journal of Molecular and Cellular Cardiology - Volume 51, Issue 4, October 2011, Pages 474–478